OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
OSI-906 is a new drug that may stop cancer cells from growing abnormally. This drug has been
used in other research studies and information from those suggests that OSI-906 may help
block cell receptors involved in tumor growth.
Gemcitabine and erlotinib are used as standard treatment for pancreatic cancer. In this
research study, the investigators are looking for the highest dose of OSI-906 that can be
given safely in combination with gemcitabine and erlotinib. This dose will then be given
together with gemcitabine and erlotinib to a further group of patients with pancreatic
cancer.